Active Pharmaceutical Ingredients CDMO Market Size, Share, Trends, Growth Outlook

Active Pharmaceutical Ingredients CDMO Market is estimated to increase at a growth rate of 7.5% CAGR over the forecast period from 2024 to 2030.

 

The Active Pharmaceutical Ingredients CDMO Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Product (Traditional Active Pharmaceutical Ingredient (Traditional API), Highly Potent Active Pharmaceutical Ingredient (HP-API), Antibody Drug Conjugate (ADC), Others), By Synthesis (Synthetic, Biotech), By Drug (Innovative, Generics), By Application (Oncology, Hormonal, Glaucoma, Cardiovascular disease, Diabetes, Others), By Workflow (Clinical, Commercial).

 

An Introduction to Active Pharmaceutical Ingredients CDMO Market in 2024

The Active Pharmaceutical Ingredient Contract Development and Manufacturing Organization (API CDMO) market in 2024 play a pivotal role in the pharmaceutical industry ecosystem, offering end-to-end solutions for the development, scale-up, and commercial manufacturing of active pharmaceutical ingredients (APIs) and intermediates. API CDMOs provide pharmaceutical companies with expertise in synthetic chemistry, process optimization, and regulatory compliance, enabling efficient and cost-effective outsourcing of API production to specialized manufacturing facilities. The market is witnessing increasing demand for API CDMO services driven by factors such as rising drug development complexity, patent expirations, and regulatory requirements for quality and safety. Moreover, the API CDMO market landscape is characterized by strategic partnerships, mergers, and acquisitions aimed at expanding service offerings, geographic footprint, and technical capabilities, thus facilitating collaboration and innovation in pharmaceutical manufacturing and accelerating drug development timelines.

 

 

Active Pharmaceutical Ingredients CDMO Market Trend: Rising Outsourcing of API Manufacturing Services

A prominent trend in the Active Pharmaceutical Ingredient Contract Development and Manufacturing Organization (API CDMO) market is the increasing outsourcing of API manufacturing services by pharmaceutical companies. With the growing complexity of drug development processes, stringent regulatory requirements, and the need for cost-effective production, pharmaceutical companies are increasingly turning to specialized CDMOs for API manufacturing. Outsourcing allows companies to leverage the expertise, infrastructure, and regulatory compliance of CDMOs, enabling them to focus on core competencies such as drug discovery, clinical development, and commercialization. This trend towards outsourcing API manufacturing services drives the growth of the API CDMO market, as pharmaceutical companies seek strategic partnerships to streamline operations, reduce manufacturing costs, and accelerate time-to-market for new drugs.

Active Pharmaceutical Ingredients CDMO Market Driver: Demand for High-Quality and Cost-Efficient API Manufacturing Solutions

A key driver fueling the growth of the API CDMO market is the increasing demand for high-quality and cost-efficient API manufacturing solutions from pharmaceutical companies. As drug development pipelines expand and become more diverse, pharmaceutical companies require reliable and flexible manufacturing partners capable of producing APIs in various therapeutic categories, dosage forms, and batch sizes. API CDMOs offer expertise in process development, scale-up, optimization, and commercial manufacturing, ensuring the production of high-quality APIs meeting regulatory standards and specifications. Additionally, outsourcing API manufacturing to CDMOs enables pharmaceutical companies to access advanced technologies, specialized equipment, and operational efficiencies, driving cost savings and enhancing competitiveness in the global market. The demand for responsive, agile, and cost-effective API manufacturing solutions propels the growth of the API CDMO market, as pharmaceutical companies seek strategic collaborations to optimize their supply chains and enhance manufacturing capabilities.

Active Pharmaceutical Ingredients CDMO Market Opportunity: Expansion of Outsourced Services into Emerging Markets

An opportunity in the API CDMO market lies in the expansion of outsourced services into emerging markets, particularly in regions with a growing pharmaceutical industry and favorable regulatory environments. Emerging markets such as Asia-Pacific, Latin America, and the Middle East offer significant growth opportunities for API CDMOs due to factors such as increasing healthcare expenditure, rising demand for generic drugs, and a growing focus on domestic drug manufacturing capabilities. By establishing strategic partnerships or subsidiaries in emerging markets, API CDMOs can leverage local expertise, infrastructure, and market knowledge to provide customized API manufacturing solutions tailored to the needs of regional pharmaceutical companies. Furthermore, expanding into emerging markets enables API CDMOs to access a diverse portfolio of drug candidates, capitalize on cost advantages, and navigate regulatory complexities, enhancing their global footprint and revenue growth potential. This opportunity enables API CDMOs to broaden their customer base, diversify revenue streams, and capitalize on the dynamic growth opportunities offered by emerging pharmaceutical markets.

 

Active Pharmaceutical Ingredients CDMO Market Segmentation

By Product

Traditional Active Pharmaceutical Ingredient (Traditional API)

Highly Potent Active Pharmaceutical Ingredient (HP-API)

Antibody Drug Conjugate (ADC)

Others

By Synthesis

Synthetic

Biotech

By Drug

Innovative

Generics

By Application

Oncology

Hormonal

Glaucoma

Cardiovascular disease

Diabetes

Others

By Workflow

Clinical

Commercial

 

Geographical Analysis

North America (United States, Canada, Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)

Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

 

Active Pharmaceutical Ingredients CDMO Market Companies

Boehringer Ingelheim International GmbH

Cambrex Corp

Catalent Inc

CordenPharma International

Lonza

Piramal Pharma Solutions

Recipharm AB

Samsung Biologics

Siegfried Holding AG

Thermo Fisher Scientific Inc

*- List Not Exhaustive

 

Reasons to Buy the Active Pharmaceutical Ingredients CDMO Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions

• Gain access to detailed insights on the Active Pharmaceutical Ingredients CDMO Market, encompassing current market size, growth trends, and forecasts till 2030.

• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities

• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends

• Identify lucrative investment avenues and expansion opportunities within the Active Pharmaceutical Ingredients CDMO Market industry, guided by robust, data-backed analysis.

• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics

• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain

• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics

• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

 

1 Introduction to 2024 Active Pharmaceutical Ingredients CDMO Market

1.1 Market Overview

1.2 Quick Facts

1.3 Scope/Objective of the Study

1.4 Market Definition

1.5 Countries and Regions Analyzed

1.6 Units, Currency, and Conversions

1.7 Industry Value Chain

 

2 Research Methodology

2.1 Market Size Estimation

2.2 Sources and Research Methodology

2.3 Data Triangulation

2.4 Assumptions and Limitations

 

3 Executive Summary

3.1 Global Active Pharmaceutical Ingredients CDMO Market Size Outlook, $ Million, 2021 to 2030

3.2 Active Pharmaceutical Ingredients CDMO Market Outlook by Type, $ Million, 2021 to 2030

3.3 Active Pharmaceutical Ingredients CDMO Market Outlook by Product, $ Million, 2021 to 2030

3.4 Active Pharmaceutical Ingredients CDMO Market Outlook by Application, $ Million, 2021 to 2030

3.5 Active Pharmaceutical Ingredients CDMO Market Outlook by Key Countries, $ Million, 2021 to 2030

 

4 Market Dynamics

4.1 Key Driving Forces of Active Pharmaceutical Ingredients CDMO Market Industry

4.2 Key Market Trends in Active Pharmaceutical Ingredients CDMO Market Industry

4.3 Potential Opportunities in Active Pharmaceutical Ingredients CDMO Market Industry

4.4 Key Challenges in Active Pharmaceutical Ingredients CDMO Market Industry

 

5 Market Factor Analysis

5.1 Competitive Landscape

5.1.1 Global Active Pharmaceutical Ingredients CDMO Market Share by Company (%), 2023

5.1.2 Product Offerings by Company

5.2 Porter’s Five Forces Analysis

 

6 Growth Outlook Across Scenarios

6.1 Growth Analysis-Case Scenario Definitions

6.2 Low Growth Scenario Forecasts

6.3 Reference Growth Scenario Forecasts

6.4 High Growth Scenario Forecasts

 

7 Global Active Pharmaceutical Ingredients CDMO Market Outlook By Segments

7.1 Active Pharmaceutical Ingredients CDMO Market Outlook by Segments

By Product

Traditional Active Pharmaceutical Ingredient (Traditional API)

Highly Potent Active Pharmaceutical Ingredient (HP-API)

Antibody Drug Conjugate (ADC)

Others

By Synthesis

Synthetic

Biotech

By Drug

Innovative

Generics

By Application

Oncology

Hormonal

Glaucoma

Cardiovascular disease

Diabetes

Others

By Workflow

Clinical

Commercial

 

8 North America Active Pharmaceutical Ingredients CDMO Market Analysis And Outlook To 2030

8.1 Introduction to North America Active Pharmaceutical Ingredients CDMO Markets in 2024

8.2 North America Active Pharmaceutical Ingredients CDMO Market Size Outlook by Country, 2021-2030

8.2.1 United States

8.2.2 Canada

8.2.3 Mexico

8.3 North America Active Pharmaceutical Ingredients CDMO Market size Outlook by Segments, 2021-2030

By Product

Traditional Active Pharmaceutical Ingredient (Traditional API)

Highly Potent Active Pharmaceutical Ingredient (HP-API)

Antibody Drug Conjugate (ADC)

Others

By Synthesis

Synthetic

Biotech

By Drug

Innovative

Generics

By Application

Oncology

Hormonal

Glaucoma

Cardiovascular disease

Diabetes

Others

By Workflow

Clinical

Commercial

 

9 Europe Active Pharmaceutical Ingredients CDMO Market Analysis And Outlook To 2030

9.1 Introduction to Europe Active Pharmaceutical Ingredients CDMO Markets in 2024

9.2 Europe Active Pharmaceutical Ingredients CDMO Market Size Outlook by Country, 2021-2030

9.2.1 Germany

9.2.2 France

9.2.3 Spain

9.2.4 United Kingdom

9.2.4 Italy

9.2.5 Russia

9.2.6 Norway

9.2.7 Rest of Europe

9.3 Europe Active Pharmaceutical Ingredients CDMO Market Size Outlook By Segments, 2021-2030

By Product

Traditional Active Pharmaceutical Ingredient (Traditional API)

Highly Potent Active Pharmaceutical Ingredient (HP-API)

Antibody Drug Conjugate (ADC)

Others

By Synthesis

Synthetic

Biotech

By Drug

Innovative

Generics

By Application

Oncology

Hormonal

Glaucoma

Cardiovascular disease

Diabetes

Others

By Workflow

Clinical

Commercial

 

10 Asia Pacific Active Pharmaceutical Ingredients CDMO Market Analysis And Outlook To 2030

10.1 Introduction to Asia Pacific Active Pharmaceutical Ingredients CDMO Markets in 2024

10.2 Asia Pacific Active Pharmaceutical Ingredients CDMO Market Size Outlook by Country, 2021-2030

10.2.1 China

10.2.2 India

10.2.3 Japan

10.2.4 South Korea

10.2.5 Indonesia

10.2.6 Malaysia

10.2.7 Australia

10.2.8 Rest of Asia Pacific

10.3 Asia Pacific Active Pharmaceutical Ingredients CDMO Market size Outlook by Segments, 2021-2030

By Product

Traditional Active Pharmaceutical Ingredient (Traditional API)

Highly Potent Active Pharmaceutical Ingredient (HP-API)

Antibody Drug Conjugate (ADC)

Others

By Synthesis

Synthetic

Biotech

By Drug

Innovative

Generics

By Application

Oncology

Hormonal

Glaucoma

Cardiovascular disease

Diabetes

Others

By Workflow

Clinical

Commercial

 

11 South America Active Pharmaceutical Ingredients CDMO Market Analysis And Outlook To 2030

11.1 Introduction to South America Active Pharmaceutical Ingredients CDMO Markets in 2024

11.2 South America Active Pharmaceutical Ingredients CDMO Market Size Outlook by Country, 2021-2030

11.2.1 Brazil

11.2.2 Argentina

11.2.3 Rest of South America

11.3 South America Active Pharmaceutical Ingredients CDMO Market size Outlook by Segments, 2021-2030

By Product

Traditional Active Pharmaceutical Ingredient (Traditional API)

Highly Potent Active Pharmaceutical Ingredient (HP-API)

Antibody Drug Conjugate (ADC)

Others

By Synthesis

Synthetic

Biotech

By Drug

Innovative

Generics

By Application

Oncology

Hormonal

Glaucoma

Cardiovascular disease

Diabetes

Others

By Workflow

Clinical

Commercial

 

12 Middle East And Africa Active Pharmaceutical Ingredients CDMO Market Analysis And Outlook To 2030

12.1 Introduction to Middle East and Africa Active Pharmaceutical Ingredients CDMO Markets in 2024

12.2 Middle East and Africa Active Pharmaceutical Ingredients CDMO Market Size Outlook by Country, 2021-2030

12.2.1 Saudi Arabia

12.2.2 UAE

12.2.3 Oman

12.2.4 Rest of Middle East

12.2.5 Egypt

12.2.6 Nigeria

12.2.7 South Africa

12.2.8 Rest of Africa

12.3 Middle East and Africa Active Pharmaceutical Ingredients CDMO Market size Outlook by Segments, 2021-2030

By Product

Traditional Active Pharmaceutical Ingredient (Traditional API)

Highly Potent Active Pharmaceutical Ingredient (HP-API)

Antibody Drug Conjugate (ADC)

Others

By Synthesis

Synthetic

Biotech

By Drug

Innovative

Generics

By Application

Oncology

Hormonal

Glaucoma

Cardiovascular disease

Diabetes

Others

By Workflow

Clinical

Commercial

 

13 Company Profiles

13.1 Company Snapshot

13.2 SWOT Profiles

13.3 Products and Services

13.4 Recent Developments

13.5 Financial Profile

List of Companies

Boehringer Ingelheim International GmbH

Cambrex Corp

Catalent Inc

CordenPharma International

Lonza

Piramal Pharma Solutions

Recipharm AB

Samsung Biologics

Siegfried Holding AG

Thermo Fisher Scientific Inc

 

14 Appendix

14.1 Customization Offerings

14.2 Subscription Services

14.3 Related Reports

14.4 Publisher Expertise

Active Pharmaceutical Ingredients CDMO Market Segmentation

By Product

Traditional Active Pharmaceutical Ingredient (Traditional API)

Highly Potent Active Pharmaceutical Ingredient (HP-API)

Antibody Drug Conjugate (ADC)

Others

By Synthesis

Synthetic

Biotech

By Drug

Innovative

Generics

By Application

Oncology

Hormonal

Glaucoma

Cardiovascular disease

Diabetes

Others

By Workflow

Clinical

Commercial

 

Geographical Analysis

North America (United States, Canada, Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)

Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)